Cargando…

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial

BACKGROUND: Axitinib demonstrated greater progression-free survival vs sorafenib in a phase III study of previously treated patients with metastatic renal cell carcinoma. Here, we report patient-reported kidney-specific symptoms and health status, measured by the Functional Assessment of Cancer Ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cella, D, Escudier, B, Rini, B, Chen, C, Bhattacharyya, H, Tarazi, J, Rosbrook, B, Kim, S, Motzer, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668468/ https://www.ncbi.nlm.nih.gov/pubmed/23579211 http://dx.doi.org/10.1038/bjc.2013.145

Ejemplares similares

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
por: Escudier, B, et al.
Publicado: (2014)

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
por: Rini, Brian I., et al.
Publicado: (2014)

Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma
por: Murphy, Danielle A, et al.
Publicado: (2020)

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
por: Martin, L P, et al.
Publicado: (2012)

Axitinib for the Management of Metastatic Renal Cell Carcinoma
por: Escudier, Bernard, et al.
Publicado: (2012)

Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours
por: Hoh, C K, et al.
Publicado: (2014)

Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
por: Ueda, Takeshi, et al.
Publicado: (2013)

Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012)

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
por: Kozloff, M F, et al.
Publicado: (2012)

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma
por: Atkins, Michael B, et al.
Publicado: (2015)

Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis
por: Cella, D, et al.
Publicado: (2010)

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
por: Motzer, R J, et al.
Publicado: (2013)

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
por: Gross-Goupil, M, et al.
Publicado: (2018)

Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study
por: Qin, Shukui, et al.
Publicado: (2015)

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
por: Quinn, D.I., et al.
Publicado: (2021)

Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
por: Chittoria, Namita, et al.
Publicado: (2016)

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α
por: Patil, S, et al.
Publicado: (2012)

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
por: Michaelson, M. Dror, et al.
Publicado: (2019)

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3
por: Meza, Luis, et al.
Publicado: (2022)

Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis
por: Wang, Hai, et al.
Publicado: (2016)

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
por: Haanen, J.B.A.G., et al.
Publicado: (2023)

Safety of axitinib and sorafenib monotherapy for patients with renal cell carcinoma: a meta-analysis
por: Qin, Fei, et al.
Publicado: (2018)

Axitinib in sequential therapy in metastatic renal cell carcinoma
por: Kuchar, Agata, et al.
Publicado: (2016)

Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101
por: Tomita, Y., et al.
Publicado: (2022)

Overall survival of first‐line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study
por: Oya, Mototsugu, et al.
Publicado: (2017)

Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study
por: Tamada, Satoshi, et al.
Publicado: (2021)

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
por: Aziz, Saadia A, et al.
Publicado: (2014)

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
por: Bracarda, S, et al.
Publicado: (2012)

Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis
por: Procopio, G, et al.
Publicado: (2013)

A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma
por: Monk, Paul, et al.
Publicado: (2014)

Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
por: Uemura, Motohide, et al.
Publicado: (2020)

Axitinib in metastatic renal cell carcinoma: single center experience
por: Buraczewska, Agnieszka, et al.
Publicado: (2017)

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma
por: Cella, D, et al.
Publicado: (2012)

Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study
por: Johnson, Alison C., et al.
Publicado: (2017)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

In vitro evaluation of Axitinib and Sorafenib treatment in glioblastoma cell viability and morphology
por: Opriţa, Alexandru, et al.
Publicado: (2023)

Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib
por: Nishimoto, Koshiro, et al.
Publicado: (2022)

Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma
por: Karakiewicz, Pierre I, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ml10qq7pcs75pjr4cb1pdn3eng